Cyclosporine A Combined with Rituximab Successfully Treated Erythropoietin-Induced Pure Red Blood Cell Aplastic Anemia.

IF 0.9 Q4 UROLOGY & NEPHROLOGY

Case Reports in Nephrology and Dialysis Pub Date : 2025-03-04 eCollection Date: 2025-01-01 DOI:10.1159/000543844

Honghui Zeng, Hong He, Xintian Shi, Ying Wang, Xin Wei

{"title":"Cyclosporine A Combined with Rituximab Successfully Treated Erythropoietin-Induced Pure Red Blood Cell Aplastic Anemia.","authors":"Honghui Zeng, Hong He, Xintian Shi, Ying Wang, Xin Wei","doi":"10.1159/000543844","DOIUrl":null,"url":null,"abstract":"Introduction: Erythropoietin-induced pure red blood cell aplastic anemia (EPO-PRCA) is a rare anemia, which presents a significant treatment challenge, often necessitating the cessation of erythropoiesis-stimulating agents and the adoption of immunosuppressive therapies or renal transplantation.Case presentation: In the present case, the patient developed severe anemia after 2-year EPO treatment and was diagnosed with EPO-PRCA. The treatment with the full dose of corticosteroids and testosterone for 1 month failed to increase his hemoglobin level significantly. Therefore, the patient received the combination therapy of cyclosporine A (CsA) with rituximab, which effectively cleared the anti-EPO antibody. Then, roxadustat was given to improve renal anemia. As Hb level increased gradually, the patient was recovered from EPO-PRCA.Conclusion: This case reported an EPO-PRCA patient was successfully cured by the combination of CsA with rituximab and provided another choice for the treatment of EPO-PRCA in the future.","PeriodicalId":9599,"journal":{"name":"Case Reports in Nephrology and Dialysis","volume":"15 1","pages":"53-59"},"PeriodicalIF":0.9000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12021380/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Nephrology and Dialysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000543844","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Erythropoietin-induced pure red blood cell aplastic anemia (EPO-PRCA) is a rare anemia, which presents a significant treatment challenge, often necessitating the cessation of erythropoiesis-stimulating agents and the adoption of immunosuppressive therapies or renal transplantation.

Case presentation: In the present case, the patient developed severe anemia after 2-year EPO treatment and was diagnosed with EPO-PRCA. The treatment with the full dose of corticosteroids and testosterone for 1 month failed to increase his hemoglobin level significantly. Therefore, the patient received the combination therapy of cyclosporine A (CsA) with rituximab, which effectively cleared the anti-EPO antibody. Then, roxadustat was given to improve renal anemia. As Hb level increased gradually, the patient was recovered from EPO-PRCA.

Conclusion: This case reported an EPO-PRCA patient was successfully cured by the combination of CsA with rituximab and provided another choice for the treatment of EPO-PRCA in the future.

查看原文本刊更多论文

环孢素A联合利妥昔单抗成功治疗促红细胞生成素诱导的纯红细胞再生障碍性贫血。

简介：促红细胞生成素诱导的纯红细胞再生障碍性贫血（EPO-PRCA）是一种罕见的贫血，其治疗具有重大挑战，通常需要停止使用促红细胞生成素药物，采用免疫抑制治疗或肾移植。病例介绍：本例患者在接受2年EPO治疗后出现严重贫血，并被诊断为EPO- prca。全剂量皮质激素和睾酮治疗1个月后，血红蛋白水平未见明显升高。因此，患者接受环孢素A （CsA）联合利妥昔单抗治疗，可有效清除抗epo抗体。然后给予罗沙司他改善肾性贫血。随着Hb水平逐渐升高，患者从EPO-PRCA中恢复。结论：本病例报告CsA联合利妥昔单抗成功治愈了EPO-PRCA患者，为今后EPO-PRCA的治疗提供了另一种选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Nephrology and Dialysis UROLOGY & NEPHROLOGY-

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of nephrology and dialysis, including genetic susceptibility, clinical presentation, diagnosis, treatment or prevention, toxicities of therapy, critical care, supportive care, quality-of-life and survival issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed.